Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.

Jamal R, Lapointe R, Cocolakis E, Thébault P, Kazemi S, Friedmann JE, Dionne J, Cailhier JF, Bélanger K, Ayoub JP, Le H, Lambert C, El-Hajjar J, van Kempen LC, Spatz A, Miller WH Jr.

J Immunother Cancer. 2017 Nov 21;5(1):83. doi: 10.1186/s40425-017-0290-x.

2.

The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system.

Reuben A, Chung JW, Lapointe R, Santos MM.

Immun Inflamm Dis. 2017 Sep;5(3):218-232. doi: 10.1002/iid3.158. Epub 2017 Apr 19. Review.

3.

Lymphocytic Microparticles Modulate Angiogenic Properties of Macrophages in Laser-induced Choroidal Neovascularization.

Tahiri H, Omri S, Yang C, Duhamel F, Samarani S, Ahmad A, Vezina M, Bussières M, Vaucher E, Sapieha P, Hickson G, Hammamji K, Lapointe R, Rodier F, Tremblay S, Royal I, Cailhier JF, Chemtob S, Hardy P.

Sci Rep. 2016 Nov 22;6:37391. doi: 10.1038/srep37391.

4.

Inflammation enhances the vaccination potential of CD40-activated B cells in mice.

Mathieu M, Odagiu L, Gaudot L, Daudelin JF, Melichar HJ, Lapointe R, Labrecque N.

Eur J Immunol. 2017 Feb;47(2):269-279. doi: 10.1002/eji.201646568. Epub 2016 Dec 27.

5.

Chitosan thermogels for local expansion and delivery of tumor-specific T lymphocytes towards enhanced cancer immunotherapies.

Monette A, Ceccaldi C, Assaad E, Lerouge S, Lapointe R.

Biomaterials. 2016 Jan;75:237-249. doi: 10.1016/j.biomaterials.2015.10.021. Epub 2015 Oct 9.

PMID:
26513416
6.

Redox-modulating agents target NOX2-dependent IKKε oncogenic kinase expression and proliferation in human breast cancer cell lines.

Mukawera E, Chartier S, Williams V, Pagano PJ, Lapointe R, Grandvaux N.

Redox Biol. 2015 Dec;6:9-18. doi: 10.1016/j.redox.2015.06.010. Epub 2015 Jun 23.

7.

T lymphocyte-derived TNF and IFN-γ repress HFE expression in cancer cells.

Reuben A, Godin-Ethier J, Santos MM, Lapointe R.

Mol Immunol. 2015 Jun;65(2):259-66. doi: 10.1016/j.molimm.2015.01.029. Epub 2015 Feb 18.

PMID:
25700349
8.

Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.

Jenabian MA, Patel M, Kema I, Vyboh K, Kanagaratham C, Radzioch D, Thébault P, Lapointe R, Gilmore N, Ancuta P, Tremblay C, Routy JP.

Clin Exp Immunol. 2014 Oct;178(1):102-11. doi: 10.1111/cei.12396.

9.

Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.

Hanafi LA, Gauchat D, Godin-Ethier J, Possamaï D, Duvignaud JB, Leclerc D, Grandvaux N, Lapointe R.

PLoS One. 2014 Jun 9;9(6):e99211. doi: 10.1371/journal.pone.0099211. eCollection 2014.

10.

The WT hemochromatosis protein HFE inhibits CD8⁺ T-lymphocyte activation.

Reuben A, Phénix M, Santos MM, Lapointe R.

Eur J Immunol. 2014 Jun;44(6):1604-14. doi: 10.1002/eji.201343955. Epub 2014 Mar 20.

11.

Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers.

Jenabian MA, Patel M, Kema I, Kanagaratham C, Radzioch D, Thébault P, Lapointe R, Tremblay C, Gilmore N, Ancuta P, Routy JP.

PLoS One. 2013 Oct 16;8(10):e78146. doi: 10.1371/journal.pone.0078146. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/11698dd2-0bc1-4fe0-ad92-b161b5594e81.

12.

mRNA PCR-based epitope chase method.

Doucet JD, Gauchat D, Lapointe R.

Methods Mol Biol. 2013;969:305-20. doi: 10.1007/978-1-62703-260-5_19. Review.

PMID:
23296942
13.

Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.

Thibodeau J, Bourgeois-Daigneault MC, Lapointe R.

Oncoimmunology. 2012 Sep 1;1(6):908-916.

14.

Cancer classification using the Immunoscore: a worldwide task force.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. Review.

15.

Stimulation of Wnt/ß-catenin pathway in human CD8+ T lymphocytes from blood and lung tumors leads to a shared young/memory phenotype.

Forget MA, Huon Y, Reuben A, Grange C, Liberman M, Martin J, Mes-Masson AM, Arbour N, Lapointe R.

PLoS One. 2012;7(7):e41074. doi: 10.1371/journal.pone.0041074. Epub 2012 Jul 30.

16.

MARCH1 down-regulation in IL-10-activated B cells increases MHC class II expression.

Galbas T, Steimle V, Lapointe R, Ishido S, Thibodeau J.

Cytokine. 2012 Jul;59(1):27-30. doi: 10.1016/j.cyto.2012.03.015. Epub 2012 Apr 12.

PMID:
22503116
17.

Improvement of the PapMV nanoparticle adjuvant property through an increased of its avidity for the antigen [influenza NP].

Savard C, Laliberté-Gagné MÈ, Babin C, Bolduc M, Guérin A, Drouin K, Forget MA, Majeau N, Lapointe R, Leclerc D.

Vaccine. 2012 Mar 28;30(15):2535-42. doi: 10.1016/j.vaccine.2012.01.085. Epub 2012 Feb 8.

PMID:
22326774
18.

CD40-activated B cells can efficiently prime antigen-specific naïve CD8+ T cells to generate effector but not memory T cells.

Mathieu M, Cotta-Grand N, Daudelin JF, Boulet S, Lapointe R, Labrecque N.

PLoS One. 2012;7(1):e30139. doi: 10.1371/journal.pone.0030139. Epub 2012 Jan 23.

19.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

20.

Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives.

Godin-Ethier J, Hanafi LA, Piccirillo CA, Lapointe R.

Clin Cancer Res. 2011 Nov 15;17(22):6985-91. doi: 10.1158/1078-0432.CCR-11-1331. Epub 2011 Nov 8. Review.

Supplemental Content

Loading ...
Support Center